Volume 12, Issue 3 (7-2022)                   JABS 2022, 12(3): 319-324 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Honarmand S, Montaseri Z, Sharafi M, Najafipoor S. A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran. JABS 2022; 12 (3) :319-324
URL: http://jabs.fums.ac.ir/article-1-2839-en.html
1- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
2- Department of Infectious Diseases, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran , montaserizahra90@gmail.com
3- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
4- Department of Microbiology, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran
Abstract:   (1066 Views)
Background & Objective: Many different combination regimens have been used for the treatment of patients infected with human immunodeficiency viruses (HIV). This study aimed to compare the efficacy of two antiviral drugs for the treatment of HIV-infected patients.
Materials & Methods: This cross-sectional study was performed on HIV-positive patients in Fasa, Southwest Iran. Eighty patients were enrolled in the investigation who were then randomly divided into two groups and treated plus vonavir (tenofovir-emtricitabine-efavirenz) and cobavir (lamivudine-zidovudine) with efavirenz for six months. Blood samples collected from all patients were examined for viral load every six months using Real-time PCR and CD4 changes by flow cytometry.
Result: During the six months of treatment, the CD4 response was not significantly increased in group one, treated with vonavir. In contrast, the CD4 value showed a significant increasing trend during the treatment course in group two treated with cobavir-efavirenz (P=0.003). However, overall, there was no statistically significant difference between the CD4 responses of the two groups (P=0.361). In addition, the plasma viral load was significantly suppressed in both regimens (P< 0.05).
Conclusion: Hence, the two regimens (cobavir-efavirenz, and vobavir) showed the same efficacy on HIV patients according to the same suppression of viral load, and CD4 response in this region. However, inclusion of more samples is needed and more studies are suggested in order to confirm our results as well.
 
Full-Text [PDF 250 kb]   (698 Downloads)    
Type of Study: Research | Subject: Infectious disease
Received: 2022/05/1 | Accepted: 2022/06/19 | Published: 2022/09/25

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advanced Biomedical Sciences

Designed & Developed by: Yektaweb

Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)